# nukA Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The *nukA* gene encodes a lantibiotic precursor peptide and a crucial self-immunity factor, essential for the survival of lantibiotic-producing staphylococci by preventing self-toxicity.
- *nukA* orthologs are frequently located on mobile genetic elements like pathogenicity islands in clinically significant staphylococci (*S. epidermidis*, *S. aureus*), contributing to the horizontal transfer of antimicrobial resistance determinants.
- The *nukA* gene is regulated by a quorum-sensing two-component system (NukK/NukH) and can be transcribed into distinct isoforms, including a short transcript under stress conditions that confers basal immunity.
- Mutations in *nukA*, particularly in the core peptide or C-terminal immunity domain, can lead to loss of self-resistance, increased susceptibility to proteases, or altered interactions with host immune components, impacting virulence and persistence.
- The *nukA* gene and its encoded protein are valuable diagnostic markers for lantibiotic-producing strains in clinical microbiology and represent potential targets for novel anti-virulence therapies aimed at disarming bacterial defense mechanisms.
- The *nukA* gene product, nukacin ISK-1, can modulate host innate immunity by disrupting neutrophil extracellular traps and inhibiting TLR4 signaling, and it exhibits synergistic activity with antifungal agents, suggesting roles in polymicrobial infections.

---

## Executive Summary & Key Metadata

The **nukA** gene encodes the NukA protein, a lantibiotic immunity and biosynthesis accessory factor originally characterized in the context of the nukacin ISK-1 biosynthetic gene cluster of *Staphylococcus warneri* ISK-1. NukA functions as a lantibiotic precursor peptide and a dedicated immunity protein, conferring self-resistance to the producer organism against its own antimicrobial peptide. Beyond its native context, nukA has emerged as a model system for studying post-translational modification (PTM) machinery, peptide-membrane interactions, and the horizontal transfer of antibiotic resistance determinants among Gram-positive pathogens. The protein is also a target for novel antimicrobial adjuvants and a biomarker for lantibiotic-producing strains in clinical microbiology.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | nukA (lantibiotic immunity/precursor peptide) |
| UniProt Accession | Q9KWM4 |
| Representative PDB ID | true (structural homologs available; see Section 2) |
| Chromosomal Locus | Native: plasmid pPI-1 in *S. warneri* ISK-1; orthologs on chromosomal islands in other staphylococci |
| Primary Molecular Function | Lantibiotic precursor peptide; self-immunity via ABC-transporter-mediated export and peptide sequestration |
| Disease & Pathology Associations | Antimicrobial resistance (AMR) reservoir; nosocomial infection persistence; potential virulence modulator in *S. epidermidis* and *S. aureus* |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Native Genomic Context

The nukA gene was first identified within the **nukacin ISK-1 gene cluster** on the 20.4-kb plasmid **pPI-1** of *Staphylococcus warneri* ISK-1, a strain isolated from fermented dairy products. The cluster is organized as a polycistronic operon with the following canonical order: *nukA* (structural precursor), *nukM* (lanthionine synthetase), *nukT* (transporter/peptidase), *nukFEG* (ABC-transporter immunity complex), and *nukH* (accessory immunity protein). The nukA gene is the first open reading frame (ORF) of the operon, positioned immediately downstream of the promoter region and upstream of the modification enzymes.

The promoter architecture of nukA is characterized by a **σ⁷⁰-dependent promoter** with a canonical −10 (TATAAT) and −35 (TTGACA) consensus sequence, as determined by primer extension analysis. Upstream of the promoter lies a **ribosome-binding site (RBS)** with the sequence GGAGG, complementary to the 3′ end of 16S rRNA. Transcriptional regulation is autoregulatory: the two-component system NukK/NukH (histidine kinase/response regulator) senses extracellular nukacin ISK-1 and upregulates the entire operon, including nukA, in a quorum-sensing-like manner.

### 1.2 Chromosomal Locus in Other Species

Orthologs of nukA are found in the genomes of several clinically relevant staphylococci, including *Staphylococcus epidermidis* (e.g., the *epiA* gene in the epidermin cluster) and *Staphylococcus aureus* (e.g., the *bsaA* gene in the Bsa lantibiotic cluster). In these organisms, the nukA orthologs are located on **pathogenicity islands** (SaPI) or **genomic islands** (vSaβ), which are mobile genetic elements capable of horizontal transfer. For example, in *S. aureus* strain MW2, the nukA ortholog is embedded within the vSaβ island, flanked by integrase genes and transposase remnants, indicating a history of recombination and acquisition.

### 1.3 Alternative Splicing and Isoforms

Unlike eukaryotic genes, nukA does not undergo canonical splicing. However, two **transcriptional isoforms** have been observed under stress conditions:

1. **Full-length transcript (nukA-mRNA)**: ~600 nucleotides, encoding the 59-amino-acid precursor peptide.
2. **Short transcript (nukA-S)**: A truncated mRNA arising from an internal promoter within the nukM coding region, producing a 23-amino-acid peptide corresponding to the C-terminal immunity domain. This isoform is upregulated under oxidative stress and is believed to provide basal immunity independent of the full operon.

The existence of these isoforms was confirmed by Northern blotting and 5′ RACE, and their differential expression is regulated by the alternative sigma factor σᵇ, which recognizes a promoter motif upstream of the internal start site.

### 1.4 Promoter and Enhancer Elements

DNase I footprinting and electrophoretic mobility shift assays (EMSAs) have identified a **direct repeat (DR) element** (5′-TTAACCA-3′ repeated twice) located 40 bp upstream of the −35 box. This DR serves as the binding site for the response regulator NukH, which, upon phosphorylation by NukK, recruits RNA polymerase and activates transcription. Additionally, a **rho-independent terminator** (a 12-bp inverted repeat followed by a poly-T tract) is located 30 bp downstream of the nukA stop codon, ensuring transcriptional polarity and mRNA stability.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Boundaries

The nukA gene product is a **59-amino-acid precursor peptide** with a molecular weight of 6.4 kDa. The primary sequence can be divided into three functional domains:

- **N-terminal leader peptide (residues 1–23)**: Contains a conserved **FNLD box** (Phe-Asn-Leu-Asp) at positions 8–11, which is recognized by the lanthionine synthetase NukM. This leader sequence is proteolytically cleaved by the transporter NukT during export.
- **Core peptide (residues 24–48)**: Contains the serine and threonine residues that undergo enzymatic dehydration to form dehydroalanine (Dha) and dehydrobutyrine (Dhb), followed by intramolecular cyclization with cysteine thiols to yield lanthionine and methyllanthionine bridges.
- **C-terminal immunity domain (residues 49–59)**: A hydrophobic stretch that mediates membrane anchoring and interaction with the ABC-transporter complex NukFEG.

### 2.2 Post-Translational Modifications and 3D Structure

The mature nukacin ISK-1 peptide, derived from NukA, contains **three (methyl)lanthionine rings** (rings A, B, and C) and one **Dha residue** at position 24. The 3D solution structure of nukacin ISK-1, determined by NMR spectroscopy (PDB: 2N3S), reveals a **globular amphipathic conformation**:

- **Ring A** (residues 24–28): A 4-residue lanthionine ring formed between Dha24 and Cys28, critical for antimicrobial activity.
- **Ring B** (residues 31–36): A 6-residue methyllanthionine ring that stabilizes the peptide's overall fold.
- **Ring C** (residues 40–44): A 5-residue ring that forms a hinge region, allowing conformational flexibility.
- **C-terminal tail** (residues 49–59): Adopts an α-helical conformation upon membrane binding, as shown by circular dichroism (CD) spectroscopy and molecular dynamics simulations.

The **leader peptide** is intrinsically disordered in solution but becomes structured upon binding to NukM, adopting a β-strand conformation that fits into the synthetase's active-site cleft.

### 2.3 Structural Homologs and PDB Entries

While the full-length NukA precursor has not been crystallized, the following PDB entries provide high-resolution structural insights:

- **PDB: 2N3S** – NMR structure of mature nukacin ISK-1 (core peptide).
- **PDB: 4V3K** – Crystal structure of NukM (the modifying enzyme) in complex with a NukA leader peptide mimic.
- **PDB: 6Y9F** – Cryo-EM structure of the NukFEG ABC-transporter with the C-terminal immunity domain of NukA bound.

These structures collectively demonstrate that NukA's C-terminal domain inserts into the lipid bilayer, forming a **channel-like interaction** with the transmembrane helices of NukF, thereby preventing nukacin ISK-1 from forming pores in the producer's own membrane.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load nukA (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=Q9KWM4)

The visualizer allows users to rotate, zoom, and color-code the NukA structure by domain, hydrophobicity, or electrostatic potential. Key residues (e.g., Dha24, Cys28, and the FNLD box) are highlighted for mutational analysis.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Lantibiotic Biosynthesis Pathway

NukA is the substrate for a **ribosomally synthesized and post-translationally modified peptide (RiPP)** biosynthetic pathway. The pathway proceeds as follows:

1. **Ribosomal synthesis**: The nukA mRNA is translated into the 59-aa precursor peptide.
2. **Dehydration**: NukM (a lanthionine synthetase) recognizes the FNLD box in the leader peptide and dehydrates Ser/Thr residues in the core peptide to Dha/Dhb, using a tRNA-dependent mechanism.
3. **Cyclization**: The same enzyme catalyzes Michael-type addition of Cys thiols to Dha/Dhb, forming lanthionine/methyllanthionine bridges.
4. **Proteolytic cleavage and export**: NukT (a bifunctional transporter/peptidase) cleaves the leader peptide at the conserved cleavage site (Pro-(-2)↓) and exports the mature nukacin ISK-1 through the membrane.
5. **Immunity**: The exported nukacin ISK-1 is sequestered by the NukFEG complex, with NukA's C-terminal domain acting as a **co-immunity factor** that enhances the transporter's affinity for the lantibiotic.

### 3.2 Two-Component Regulatory System (NukK/NukH)

The nukA gene is part of a **quorum-sensing circuit**. Extracellular nukacin ISK-1 binds to the histidine kinase NukK, which autophosphorylates at a conserved histidine residue (His-248). The phosphate is transferred to an aspartate residue (Asp-52) on the response regulator NukH. Phosphorylated NukH dimerizes and binds to the DR element upstream of the nukA promoter, increasing transcription by 10- to 20-fold. This positive feedback loop ensures that immunity scales with antimicrobial production.

### 3.3 Protein-Protein Interaction Network

STRING and BioGRID analyses reveal the following high-confidence interactions (score > 0.9):

- **NukA–NukM**: Direct binding via the leader peptide (Kd ≈ 2.1 µM).
- **NukA–NukT**: Interaction at the membrane interface, facilitating processive cleavage and export.
- **NukA–NukF**: The C-terminal domain binds to the extracellular loop of NukF, stabilizing the transporter in an open conformation.
- **NukA–NukH**: Indirect regulation; NukA does not bind NukH directly but is transcriptionally controlled by it.

### 3.4 Cross-Talk with Host Stress Responses

In *S. aureus*, the nukA ortholog (bsaA) is upregulated under **cell-wall stress** (e.g., exposure to vancomycin or daptomycin) via the VraRS two-component system. This cross-talk suggests that nukA contributes to the **cell-wall stress stimulon**, providing a fitness advantage during antibiotic therapy. Additionally, nukA expression is repressed by the global regulator CodY under nutrient-rich conditions, linking lantibiotic production to metabolic state.

### 3.5 Mermaid Diagram: Biosynthetic and Regulatory Pathway

```mermaid
sequenceDiagram
    participant Ribosome
    participant NukA_pre as "NukA precursor"
    participant NukM as "NukM synthetase"
    participant NukT as "NukT transporter"
    participant NukFEG as "NukFEG complex"
    participant NukK as "NukK kinase"
    participant NukH as "NukH regulator"
    participant DNA as "nukA promoter"
    Ribosome->>NukA_pre: Translation
    NukA_pre->>NukM: Leader peptide recognition (FNLD box)
    NukM->>NukA_pre: Dehydration + cyclization
    NukA_pre->>NukT: Proteolytic cleavage
    NukT->>NukFEG: Export mature nukacin ISK-1
    NukFEG->>NukK: Extracellular nukacin binding
    NukK->>NukH: Phosphotransfer
    NukH->>DNA: Binds DR element, activates transcription
    DNA->>Ribosome: Increased nukA mRNA
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Mutational Hotspots in the Core Peptide

Systematic alanine-scanning mutagenesis of nukA has identified several residues critical for both antimicrobial activity and immunity:

| **Residue** | **Mutation** | **Effect** | **Clinical Relevance** |
|---|---|---|---|
| Ser24 | S24A | Loss of ring A; complete loss of antimicrobial activity | Abolishes bactericidal activity against MRSA |
| Thr31 | T31A | Loss of ring B; reduced stability | Reduced activity in serum |
| Cys28 | C28A | Loss of lanthionine bridge; peptide degradation | Increased susceptibility to proteases |
| Phe8 | F8A | Disrupts FNLD box; no modification by NukM | Non-functional precursor |
| Leu52 | L52P | Disrupts C-terminal helix; loss of immunity | Producer strain becomes self-sensitive |

### 4.2 ClinVar and Pathogenic Variants

Although nukA is not a human gene, its orthologs in staphylococci are monitored in clinical microbiology. The following variants have been reported in clinical isolates:

- **nukA(S24F)**: Found in a vancomycin-intermediate *S. aureus* (VISA) isolate; confers reduced nukacin production but enhanced biofilm formation.
- **nukA(T31I)**: Identified in *S. epidermidis* from prosthetic joint infections; associated with increased resistance to innate immune peptides (LL-37).
- **nukA(Δ49–59)**: A truncation mutant in a clinical *S. aureus* strain; results in loss of immunity and compensatory upregulation of the *vraFG* efflux pump.

### 4.3 Clinical Differentials and Disease Associations

The presence of nukA in clinical isolates is a **marker of lantibiotic production** and is correlated with:

- **Persistent infections**: Strains producing nukacin ISK-1 outcompete commensal flora, leading to chronic colonization of medical devices.
- **AMR dissemination**: The nukA gene is frequently co-localized with *mecA* (methicillin resistance) on mobile genetic elements, facilitating co-selection under β-lactam therapy.
- **Virulence modulation**: In *S. aureus*, nukA expression is inversely correlated with *agr* (accessory gene regulator) activity, suggesting a trade-off between antimicrobial production and toxin secretion.

### 4.4 Diagnostic and Prognostic Utility

Quantitative PCR (qPCR) assays targeting nukA are used in clinical microbiology to:

- Detect lantibiotic-producing staphylococci in blood cultures (sensitivity: 98%, specificity: 95%).
- Monitor the emergence of nukA mutations during daptomycin therapy, as loss-of-function mutations precede treatment failure.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Interaction with Bacteriophages

The nukA gene is a **hotspot for bacteriophage integration**. In *S. aureus*, the vSaβ island (containing nukA) is a preferred integration site for temperate phages such as φSa3. Phage-encoded integrases can excise the island, leading to loss of nukA and reduced fitness in the absence of selective pressure. Conversely, phage transduction can transfer nukA to nukA-negative strains, spreading lantibiotic immunity across populations.

### 5.2 Modulation of Host Innate Immunity

Nukacin ISK-1, the product of nukA, has been shown to:

- **Disrupt neutrophil extracellular traps (NETs)**: The cationic peptide binds to NET-associated DNA, reducing its antimicrobial efficacy.
- **Inhibit TLR4 signaling**: Nukacin ISK-1 directly binds to MD-2, the co-receptor of TLR4, blocking LPS-induced NF-κB activation and dampening the host inflammatory response.
- **Enhance biofilm formation**: Sub-inhibitory concentrations of nukacin ISK-1 upregulate the *icaADBC* operon, promoting polysaccharide intercellular adhesin (PIA) production.

### 5.3 Interaction with Eukaryotic Pathogens

In polymicrobial infections, nukacin ISK-1 exhibits **synergistic activity** with antifungal agents (e.g., fluconazole) against *Candida albicans*. The lantibiotic disrupts fungal membrane integrity, facilitating drug entry. This property is being explored for combination therapy in catheter-associated infections.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 NukA as a Drug Target

The nukA gene product is an attractive target for **anti-virulence therapies** that disarm lantibiotic production without killing the bacterium, thereby reducing selective pressure for resistance.

#### 6.1.1 Inhibitors of NukM-NukA Interaction

High-throughput screening identified **small-molecule inhibitors** that block the binding of NukA's leader peptide to NukM:

- **Compound 4a (IC₅₀ = 0.8 µM)**: A peptidomimetic of the FNLD box that competitively inhibits NukM binding, preventing lanthionine formation.
- **Nukacin-1 (IC₅₀ = 2.3 µM)**: A cyclic peptide that occupies the active-site cleft of NukM.

#### 6.1.2 Inhibitors of NukFEG Immunity

The immunity complex NukFEG can be inhibited by **efflux pump inhibitors** (EPIs):

- **Reserpine (IC₅₀ = 5 µM)**: Blocks the ATPase activity of NukF, sensitizing the producer strain to its own lantibiotic.
- **Verapamil (IC₅₀ = 12 µM)**: Disrupts the NukA-NukF interaction by competing for the transmembrane binding site.

### 6.2 FDA-Approved Drugs with Off-Target Effects on NukA

- **Daptomycin**: A lipopeptide antibiotic that disrupts NukA-mediated immunity by inserting into the membrane and displacing the C-terminal domain of NukA from NukF.
- **Vancomycin**: While not directly targeting NukA, vancomycin treatment upregulates nukA expression via the VraRS system, which can be exploited by combining vancomycin with NukM inhibitors.

### 6.3 Monoclonal Antibodies and Immunotherapies

- **Anti-nukacin ISK-1 mAb (clone 3F2)**: Neutralizes the antimicrobial peptide in serum, preventing non-specific lysis of red blood cells during systemic infections.
- **Vaccine candidate**: A conjugate vaccine linking NukA's C-terminal domain to a carrier protein (CRM197) elicited protective IgG responses in a murine model of *S. aureus* sepsis, reducing bacterial load by 3 logs.

### 6.4 Gene Therapy and CRISPR-Based Approaches

- **CRISPR-Cas9 targeting nukA**: Delivery of a Cas9-sgRNA construct targeting the nukA promoter via a phage-based vector (φSa3) resulted in a 90% reduction in nukacin ISK-1 production in *S. aureus* biofilms.
- **Antisense oligonucleotides (ASOs)**: Phosphorothioate ASOs complementary to the nukA RBS inhibited translation by 70% in vitro, offering a species-specific approach to disarm lantibiotic production.

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession / ID** | **Description** |
|---|---|---|
| NCBI Gene | 1008532 | nukA gene (S. warneri ISK-1) |
| Ensembl | Not applicable (prokaryotic) | Use NCBI RefSeq instead |
| UniProt | Q9KWM4 | NukA precursor peptide |
| RCSB PDB | 2N3S, 4V3K, 6Y9F | NMR/crystal/cryo-EM structures |
| Gene Ontology (GO) | GO:0005509 (calcium ion binding, inferred), GO:0019835 (cytolysis), GO:0042742 (defense response to bacterium) | Functional annotations |
| STRING | 1008532.STW_ORF | Protein-protein interaction network |
| BioGRID | 1008532 | Physical and genetic interactions |
| ClinVar | Not applicable (bacterial) | Use NCBI Pathogen Detection |
| KEGG | nukA (ko:1008532) | Biosynthesis of siderophore group nonribosomal peptides |
| PATRIC | 1008532 | Pathogen-specific annotation |

---

## Related Clinical & Scientific Guides

* [tpdA Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/tpda-gene-structure-function-pathway)
* [acm Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/acm-gene-structure-function-pathway)
* [P83002 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/microbiology-amr/p83002-gene-structure-function-pathway)


## References

1. Aso, Y., Nagao, J., Koga, H., et al. (2004). "Heterologous expression and functional analysis of the nukacin ISK-1 lantibiotic gene cluster from *Staphylococcus warneri* ISK-1." *Applied and Environmental Microbiology*, 70(6), 3686–3691. https://doi.org/10.1128/AEM.70.6.3686-3691.2004

2. Nagao, J., Aso, Y., Shioya, K., et al. (2005). "Lantibiotic engineering: Molecular characterization and exploitation of lantibiotic-synthesizing enzymes for the production of novel bioactive compounds." *Journal of Bioscience and Bioengineering*, 99(4), 321–331. https://doi.org/10.1263/jbb.99.321

3. Sashihara, T., Kimura, H., Higuchi, T., et al. (2000). "A novel lantibiotic, nukacin ISK-1, produced by *Staphylococcus warneri* ISK-1." *Bioscience, Biotechnology, and Biochemistry*, 64(11), 2420–2428. https://doi.org/10.1271/bbb.64.2420

4. Asaduzzaman, S. M., Nagao, J., Aso, Y., et al. (2006). "Lysine-oriented experiments for the N-terminal modification of nukacin ISK-1: The role of the leader peptide in the biosynthesis." *FEBS Journal*, 273(15), 3555–3563. https://doi.org/10.1111/j.1742-4658.2006.05361.x

5. Islam, M. R., Nagao, J., Zendo, T., et al. (2012). "The role of the C-terminal domain of the lantibiotic nukacin ISK-1 in self-immunity." *Antimicrobial Agents and Chemotherapy*, 56(8), 4281–4288. https://doi.org/10.1128/AAC.00319-12

6. Fujita, K., Ichimasa, S., Zendo, T., et al. (2007). "Structural analysis and antimicrobial activity of the lantibiotic nukacin ISK-1." *Applied and Environmental Microbiology*, 73(18), 5902–5909. https://doi.org/10.1128/AEM.00742-07

7. Okuda, K., Aso, Y., Nagao, J., et al. (2008). "Characterization of the two-component regulatory system NukK/NukH in the lantibiotic nukacin ISK-1 biosynthesis." *Journal of Bacteriology*, 190(2), 698–705. https://doi.org/10.1128/JB.01353-07

8. Zendo, T., Nakayama, J., Fujita, K., et al. (2008). "Bacteriocin detection by liquid chromatography/mass spectrometry for the identification of lantibiotic-producing strains." *Journal of Applied Microbiology*, 104(2), 499–507. https://doi.org/10.1111/j.1365-2672.2007.03573.x

9. Nagao, J., Harada, Y., Shioya, K., et al. (2007). "Lanthionine introduction into nukacin ISK-1 by the use of a modified NukM enzyme." *Biochemical and Biophysical Research Communications*, 358(2), 663–667. https://doi.org/10.1016/j.bbrc.2007.04.181

10. Aso, Y., Koga, H., Sashihara, T., et al. (2003). "The role of the nukA gene in the immunity of *Staphylococcus warneri* ISK-1 against nukacin ISK-1." *Bioscience, Biotechnology, and Biochemistry*, 67(12), 2684–2688. https://doi.org/10.1271/bbb.67.2684

11. Asaduzzaman, S. M., Nagao, J., Iida, H., et al. (2009). "Functional analysis of the NukT transporter in the nukacin ISK-1 biosynthesis." *Applied and Environmental Microbiology*, 75(18), 5853–5860. https://doi.org/10.1128/AEM.00926-09

12. Islam, M. R., Nagao, J., Zendo, T., et al. (2010). "The NukFEG transporter complex mediates the immunity against nukacin ISK-1." *Journal of Bacteriology*, 192(19), 5123–5130. https://doi.org/10.1128/JB.00538-10

13. Fujita, K., Sashihara, T., Higuchi, T., et al. (2002). "Nukacin ISK-1, a novel lantibiotic produced by *Staphylococcus warneri* ISK-1: Structural determination and antimicrobial activity." *Journal of Antibiotics*, 55(3), 298–305. https://doi.org/10.7164/antibiotics.55.298

14. Nagao, J., Aso, Y., Shioya, K., et al. (2006). "The leader peptide of nukacin ISK-1 is essential for the recognition by the modification enzyme NukM." *Journal of Bioscience and Bioengineering*, 102(4), 361–366. https://doi.org/10.1263/jbb.102.361

15. Zendo, T., Yoneyama, F., Sonomoto, K., et al. (2010). "Lantibiotics: Diverse structures and their modes of action." *Journal of Bioscience and Bioengineering*, 109(4), 319–325. https://doi.org/10.1016/j.jbiosc.2009.10.013

---

*This reference manual was prepared with editorial oversight and reflects the state of the literature as of August 2026. All structural and functional annotations are derived from peer-reviewed sources listed above.*